Recruiting
A Study to Evaluate the Drug Levels, Efficacy and Safety of BMS-986165 in Adolescent Participants With Moderate to Severe Plaque Psoriasis - IM011-126
Oppdatert:
31 oktober, 2024
|
ClinicalTrials.gov
Fase
Kjønn
Aldersgruppe
Sted(er)
Recruiting
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - Males and females aged 12 to <18 years - Plaque psoriasis for at least 6 months - Moderate to severe disease - Candidate for phototherapy or systemic therapy Exclusion Criteria: - Weighing ≤ 30.0 kg at screening - Other forms of psoriasis - History of recent infection - Prior exposure to BMS-986165 or active comparator Other protocol-defined inclusion/exclusion criteria apply
Vi anbefaler at du kontakter BMS for å rapportere bivirkninger.
Bivirkninger (uønskede hendelser) og andre rapporterbare hendelser er definert her
For å rapportere bivirkninger (uønskede hendelser) eller reklamere på et legemiddel: Medisinsk informasjon
MLTNO2000046